Nanocarriers for Magnetically Actuated Targeted Drug Delivery

Vrinda Sant,Liping Wang,Grace Jang,Deependra Ban,Jay Seth,Sami Kazmi,Nirav R. Patel,Qingqing Yang,Joon Lee,Woraphong Janetanakit,Shanshan Wang,Brian Head,Gennadi Glinsky,Ratnesh Lal
DOI: https://doi.org/10.1016/j.bpj.2018.11.220
IF: 3.4
2019-01-01
Biophysical Journal
Abstract:Nanoparticles carrying therapeutics have emerged as promising candidates for targeted drug delivery. These nanocarriers (NC) can initiate controlled and on-demand release at the target site. However, obtaining effective doses of NCs in diseased locations remains challenging. Magnetic NCs (MNCs) can be used as vectors to increase localized bioavailability of drug: external magnetic fields can accumulate MNCs at a target site and trigger controlled release of therapeutics in high concentrations. Additionally, dynamic magnetic field gradients can potentially guide MNCs through blood vessel networks, increasing the amount of therapeutic reaching the target site. In our lab, we have designed two types of iron oxide- silica MNCs - magnetic gold nano-golf-balls (NGB) and magnetic nanobowls (NB). These MNCs were functionalized for pH and temperature stimuli sensitive drug release. NGB and NB response to magnetic field was analyzed by microscopy in: (1) epithelial HeLa cells, (2) neurons derived from induced pluripotent stem cells (iPSCs), (3) porous hydrogels and (3) microfluidic systems. Magnetic fields increase uptake of NGBs in HeLa cells and neurons. Stimuli sensitive drug release was demonstrated by encapsulating DOX in NGB. Magnetically actuated transport in hydrogels suggests that these MNCs can be retained for long periods of time in high elastic modulus tissues. Studying NBs in microfluidic systems revealed characteristics of their response to magnetic field gradients in varied fluid flow conditions. These findings enhance our understanding of factors affecting efficiency for magnetically guided transport, namely, magnetic and hydrodynamic volume and magnetization of MNCs. Optimization of these factors in MNCs can reduce side-effects by enabling guided drug delivery through vasculature to a target site.
What problem does this paper attempt to address?